Met Provides Essential Signals for Liver Regeneration

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2004 Jul 14

PMID 15249655

Citations 205

Authors

Malgorzata Borowiak

Alistair N Garratt

Torsten Wustefeld

Michael Strehle

Christian Trautwein

Carmen Birchmeier

Affiliations

Soon will be listed here.

Abstract

Genetic analysis in mice has demonstrated a crucial role of the Met tyrosine kinase receptor and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), in development of the liver, muscle, and placenta. Here, we use conditional mutagenesis in mice to analyze the function of Met during liver regeneration, using the Mx-cre transgene to introduce the mutation in the adult. After partial hepatectomy in mice carrying the Mx-cre-induced Met mutation, regeneration of the liver is impaired. Comparison of signal transduction pathways in control and mutant livers indicates that Met and other signaling receptors cooperate to fully activate particular signaling molecules, for instance, the protein kinase Akt. However, activation of the Erk1/2 kinase during liver regeneration depends exclusively on Met. Signaling crosstalk is thus an important aspect of the regulation of liver regeneration. Analysis of cell cycle progression of hepatocytes in conditional Met mutant mice indicates a defective exit from quiescence and diminished entry into S phase. Impaired liver regeneration is accompanied by compensatory physiological responses that include prolonged up-regulation of HGF/SF and IL-6 in peripheral blood. Our data demonstrate that the HGF/SF/Met signaling system is essential not only during liver development but also for the regeneration of the organ in the adult.

Citing Articles

Granulocyte colony-stimulating factor reduces biliary fibrosis and ductular reaction in a mouse model of chronic cholestasis.

Le T, Dang T, Do H, Holterman A, Phan-Thi H, Tran T Liver Res. 2025; 7(1):90-98.

PMID: 39959697 PMC: 11791853. DOI: 10.1016/j.livres.2023.02.004.

MET Activation in Lung Cancer and Response to Targeted Therapies.

Okun S, Lu D, Sew K, Subramaniam A, Lockwood W Cancers (Basel). 2025; 17(2).

PMID: 39858062 PMC: 11764361. DOI: 10.3390/cancers17020281.

Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.

Matsuda T, Kaji K, Nishimura N, Asada S, Koizumi A, Tanaka M Heliyon. 2024; 10(19):e38647.

PMID: 39398008 PMC: 11470516. DOI: 10.1016/j.heliyon.2024.e38647.

Adverse effects of graft congestion and ameliorative effects of hepatocyte growth factor after liver transplantation in rats.

Aoki H, Ito T, Hirata M, Okumura S, Masano Y, Ogawa E Liver Transpl. 2024; 31(1):11-23.

PMID: 39225679 PMC: 11643138. DOI: 10.1097/LVT.0000000000000449.

A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model.

Rojas-Chaverra N, Imamura R, Sato H, Passioura T, Mihara E, Nishimura T iScience. 2024; 27(8):110426.

PMID: 39108737 PMC: 11300919. DOI: 10.1016/j.isci.2024.110426.

References

Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T . Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000; 106(12):1511-9. PMC: 387252. DOI: 10.1172/JCI10226. View

Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V . Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology. 1999; 29(2):403-11. DOI: 10.1002/hep.510290244. View

Matsumoto K, Nakamura T . Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001; 59(6):2023-38. DOI: 10.1046/j.1523-1755.2001.00717.x. View

Trimarchi J, Lees J . Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002; 3(1):11-20. DOI: 10.1038/nrm714. View

Behrens A, Sibilia M, David J, Tronche F, Schutz G, Wagner E . Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 2002; 21(7):1782-90. PMC: 125360. DOI: 10.1093/emboj/21.7.1782. View

Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S . Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene. 2002; 21(15):2309-19. DOI: 10.1038/sj.onc.1205297. View

Picard C, Lambotte L, Starkel P, Sempoux C, Saliez A, Van Den Berge V . Steatosis is not sufficient to cause an impaired regenerative response after partial hepatectomy in rats. J Hepatol. 2002; 36(5):645-52. DOI: 10.1016/s0168-8278(02)00038-7. View

Torbenson M, Yang S, Liu H, Huang J, Gage W, Diehl A . STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol. 2002; 161(1):155-61. PMC: 1850692. DOI: 10.1016/S0002-9440(10)64167-3. View

Li W, Liang X, Kellendonk C, Poli V, Taub R . STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 2002; 277(32):28411-7. DOI: 10.1074/jbc.M202807200. View

10.

Jin H, Yang R, Li W, Ogasawara A, Schwall R, Eberhard D . Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J Pharmacol Exp Ther. 2003; 304(2):654-60. DOI: 10.1124/jpet.102.041772. View

11.

Kiso S, Kawata S, Tamura S, Inui Y, Yoshida Y, Sawai Y . Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology. 2003; 124(3):701-7. DOI: 10.1053/gast.2003.50097. View

12.

Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S . A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994; 77(2):261-71. DOI: 10.1016/0092-8674(94)90318-2. View

13.

Wuestefeld T, Klein C, Streetz K, Betz U, Lauber J, Buer J . Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem. 2003; 278(13):11281-8. DOI: 10.1074/jbc.M208470200. View

14.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

15.

Park M, Dean M, Cooper C, Schmidt M, OBrien S, Blair D . Mechanism of met oncogene activation. Cell. 1986; 45(6):895-904. DOI: 10.1016/0092-8674(86)90564-7. View

16.

Stoker M, Gherardi E, Perryman M, Gray J . Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987; 327(6119):239-42. DOI: 10.1038/327239a0. View

17.

Zarnegar R, Michalopoulos G . Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 1989; 49(12):3314-20. View

18.

Miyazawa K, Tsubouchi H, Naka D, Okigaki M, Arakaki N, Nakayama H . Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989; 163(2):967-73. DOI: 10.1016/0006-291x(89)92316-4. View

19.

Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A . Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342(6248):440-3. DOI: 10.1038/342440a0. View

20.

Bottaro D, Rubin J, Faletto D, Chan A, Kmiecik T, Woude G . Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251(4995):802-4. DOI: 10.1126/science.1846706. View